Why Earnings Season Could Be Great for Zentalis (ZNTL)
Investors are always looking for stocks that are poised to beat at earnings season and Zentalis Pharmaceuticals, Inc. ZNTL may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Zentalis is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ZNTL in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 66 cents per share for ZNTL, compared to a broader Zacks Consensus Estimate of a loss of 97 cents per share. This suggests that analysts have very recently bumped up their estimates for ZNTL, giving the stock a Zacks Earnings ESP of +31.82% heading into earnings season.
Zentalis Pharmaceuticals, Inc. Price and EPS Surprise
Zentalis Pharmaceuticals, Inc. price-eps-surprise | Zentalis Pharmaceuticals, Inc. Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that ZNTL has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Zentalis, and that a beat might be in the cards for the upcoming report.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zentalis Pharmaceuticals, Inc. (ZNTL) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
